Weekly Taxanes in the Treatment of Metastatic Breast Cancer | Zendy

HansJoachim Lück | Zendy; P. Vogel | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Weekly Taxanes in the Treatment of Metastatic Breast Cancer

Author(s) -

HansJoachim Lück,

P. Vogel

Publication year - 2006

Publication title -

breast care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.767

H-Index - 30

eISSN - 1661-3805

pISSN - 1661-3791

DOI - 10.1159/000093986

Subject(s) - medicine , taxane , tolerability , paclitaxel , trastuzumab , oncology , carboplatin , metastatic breast cancer , bevacizumab , schedule , breast cancer , cancer , chemotherapy , adverse effect , cisplatin , computer science , operating system

Taxanes were developed in the 1990s for the treatment of metastatic breast cancer. Beginning with a 3-weekly schedule, in the last years the weekly schedule, especially for paclitaxel, became more and more common. The weekly schedules are characterized by a lower rate of side effects and better tolerability. The weekly taxane schedules are also a good platform for combinations with Carboplatin, Trastuzumab or Bevacizumab.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research